INA17 Antibody

What is INA17 and why are antibodies against it significant in research?

INA17 (also known as Ina17) is an integral membrane protein localized to the inner mitochondrial membrane with a calculated molecular weight of 21.8 kDa. It contains a predicted presequence, a single hydrophobic amino acid stretch sufficient to form a transmembrane span, and a predicted coiled-coil domain . INA17 plays a crucial role in the assembly of the peripheral stalk of mitochondrial F₁Fₒ-ATP synthase, which is essential for cellular energy production. Antibodies against INA17 are significant research tools because they allow for specific detection, quantification, and functional analysis of this protein in mitochondrial assembly studies. The C-terminal domain of INA17 is exposed to the intermembrane space (IMS), making it accessible for antibody binding in certain experimental conditions .

How does INA17 function in mitochondrial ATP synthase assembly?

INA17 functions as part of the INA complex that facilitates the assembly of the peripheral stalk of mitochondrial ATP synthase. Mass spectrometric analyses revealed significant enrichment of INA17 in INA22 complex purification, indicating their close functional relationship . When INA17 is absent, similar to INA22 deletion, there is dissociation of the F₁-portion from the Fₒ-complex in mitochondria. This results in:

• A four to five fold increase in free F₁-portion in mitochondria

• Reduced amounts of ATP synthase monomers

• Presence of free F₁-subcomplexes not connected to Fₒ-domains

These findings demonstrate that INA17 specifically affects the organization and stability of the ATP synthase complex rather than directly impacting its catalytic activity.

What experimental methods can confirm INA17 localization in mitochondria?

Multiple complementary methods can be used to confirm the mitochondrial localization of INA17:

• Import assays: Radiolabeled INA17 can be incubated with purified mitochondria to demonstrate Δψ-dependent import and processing to a faster migrating mature form, confirming transport across the inner membrane .

• Alkaline extraction: Subjecting purified mitochondria to alkaline treatment and observing that INA17 is only released by detergent solubilization confirms it as an integral membrane protein .

• Protease protection experiments: INA17 resistance to protease treatment in intact mitochondria but accessibility upon outer membrane rupture through hypoosmotic treatment helps determine its topology and submitochondrial localization .

• Immunofluorescence microscopy: Using antibodies against INA17 and co-staining with established mitochondrial markers can visually confirm its localization.

How can researchers distinguish between specific and non-specific binding when using INA17 antibodies?

Distinguishing specific from non-specific binding is critical for accurate experimental interpretations. Researchers should implement the following validation strategies:

• Knockdown/knockout controls: Compare antibody signal between wild-type samples and those where INA17 expression has been reduced or eliminated through shRNA or gene deletion .

• Competition assays: Pre-incubation of the antibody with purified INA17 protein before staining should diminish specific signal but not non-specific binding.

• Multiple antibody comparison: Utilize antibodies targeting different epitopes of INA17 to confirm signal patterns.

• Binding mode identification: Apply computational modeling approaches to identify distinct binding modes associated with specific and non-specific interactions, as demonstrated in antibody specificity studies .

The specificity of antibody binding can be mathematically modeled with the following relationship:

$E = \sum_{w} \pi_w E_w$

Where E represents the total binding energy, π_w is the probability of binding mode w, and E_w is the energy associated with binding mode w .

What experimental challenges exist in studying INA17-antibody interactions in mitochondrial contexts?

Studying INA17-antibody interactions in mitochondrial contexts presents several unique challenges:

• Membrane barrier penetration: Since INA17 is an integral membrane protein with only certain domains exposed to different compartments, antibody accessibility is limited in intact mitochondria .

• Conformational changes: INA17's structure may differ when integrated into the ATP synthase assembly compared to its isolated form, potentially affecting epitope recognition.

• Cross-reactivity with related proteins: Ensuring antibody specificity against other mitochondrial assembly factors with similar structural domains.

• Low abundance: The relative abundance of INA17 may require sensitive detection methods and signal amplification techniques.

• Preservation of native structure: Extraction methods must maintain protein structure while making it accessible to antibodies.

How does antibody binding affect INA17 function in ATP synthase assembly?

The impact of antibody binding on INA17 function is a critical consideration for interference assays. When antibodies bind to INA17, they may:

• Block protein-protein interactions: Inhibit the association between INA17 and other components of the INA complex or ATP synthase subunits.

• Alter conformational dynamics: Change the structural flexibility needed for INA17 to facilitate assembly.

• Disrupt membrane integration: Affect the stability of INA17 within the inner mitochondrial membrane.

To assess these effects, researchers can perform ATP synthase assembly assays in the presence of different INA17 antibody concentrations and compare assembly efficiency through BN-PAGE analysis and ATPase activity measurements. Dose-dependent effects would indicate specific interference with INA17 function rather than non-specific effects on mitochondrial integrity.

What are the optimal protocols for INA17 antibody generation?

Generating high-quality antibodies against INA17 requires careful consideration of several factors:

• Antigen selection: Based on the INA17 topology, the C-terminal domain exposed to the intermembrane space represents an accessible target for antibody generation . Alternatively, synthetic peptides corresponding to unique regions of INA17 can be used as immunogens.

• Antibody format selection: For research applications, both polyclonal and monoclonal antibodies have value:

  • Polyclonal antibodies provide broader epitope recognition

  • Monoclonal antibodies offer higher reproducibility and specificity

• Production methods:

  • Recombinant expression of the C-terminal domain of INA17 in E. coli

  • Purification under native or denaturing conditions depending on solubility

  • Conjugation to carrier proteins for enhanced immunogenicity

• Validation steps:

  • Western blotting against mitochondrial fractions from wild-type and INA17-knockout cells

  • Immunoprecipitation followed by mass spectrometry to confirm target capture

  • Immunofluorescence with colocalization studies

The selection of immunization strategy should balance between generating antibodies with high specificity and those capable of recognizing native conformations of INA17.

How can researchers optimize INA17 antibody specificity using computational approaches?

Advanced computational approaches can enhance antibody specificity for INA17:

• Epitope mapping and optimization: Computational analysis of the INA17 sequence can identify unique regions with low homology to other proteins, maximizing specificity.

• Binding mode identification: As demonstrated in antibody specificity studies, computational models can identify distinct binding modes associated with specific targets .

• Energy function optimization: To design antibodies with customized specificity profiles, researchers can optimize energy functions associated with desired binding modes while maximizing those associated with undesired targets .

The computational design approach follows this principle:

$\text{For specific binding}: \text{minimize } E_{\text{target}} \text{ and maximize } E_{\text{non-target}}$

$\text{For cross-reactive binding}: \text{jointly minimize } E \text{ for all desired targets}$

Where E represents the binding energy functions associated with each mode .

What techniques provide the most robust detection of INA17 in complex biological samples?

For robust detection of INA17 in complex samples, researchers should consider:

• Sample preparation optimization:

  • Isolation of highly purified mitochondria to enrich for INA17

  • Appropriate solubilization conditions that preserve structural integrity

  • Subcellular fractionation to separate inner membrane components

• Detection techniques comparison:

• Signal enhancement strategies:

  • Tyramide signal amplification for immunofluorescence

  • Enhanced chemiluminescence for Western blotting

  • Multiple epitope targeting with antibody cocktails

• Validation controls:

  • Include INA17-deficient samples as negative controls

  • Use competing peptides to confirm signal specificity

  • Implement both N-terminal and C-terminal targeting antibodies

How should researchers interpret conflicting results between different INA17 antibody-based assays?

When facing conflicting results across different antibody-based assays, researchers should:

• Evaluate epitope accessibility: Different experimental conditions may expose or mask epitopes. For example, the C-terminal domain of INA17 is exposed to the intermembrane space and might be accessible only under certain conditions .

• Consider post-translational modifications: Modifications might affect epitope recognition in some assays but not others.

• Assess antibody cross-reactivity: Validate specificity through knockout controls in each experimental system.

• Examine protein complex associations: INA17's incorporation into larger complexes may shield epitopes in certain assays.

• Implement orthogonal approaches: Complement antibody-based techniques with antibody-independent methods such as mass spectrometry or functional assays.

What are the best practices for analyzing INA17 antibody binding kinetics?

Analysis of binding kinetics provides critical insights into antibody quality and behavior:

• Measurement techniques:

  • Surface Plasmon Resonance (SPR) for real-time binding analysis

  • Bio-Layer Interferometry (BLI) for label-free interaction studies

  • Isothermal Titration Calorimetry (ITC) for thermodynamic parameters

• Key parameters to evaluate:

  • Association rate constant (kon)

  • Dissociation rate constant (koff)

  • Equilibrium dissociation constant (KD = koff/kon)

• Experimental design considerations:

  • Use purified recombinant INA17 or representative peptides

  • Test binding under varying pH and ionic strength conditions

  • Compare binding to wild-type and mutant variants of INA17

• Data interpretation:

  • High-affinity antibodies: KD in nM to pM range

  • Fast association (high kon): Efficient binding in dilute solutions

  • Slow dissociation (low koff): Stable binding for detection applications

Results should be reported with appropriate statistical analysis and consideration of experimental limitations such as immobilization effects or conformational constraints.

How can INA17 antibodies be utilized to study mitochondrial diseases?

INA17 antibodies serve as valuable tools for investigating mitochondrial disorders:

• Diagnostic applications:

  • Analyzing INA17 expression levels in patient samples

  • Assessing ATP synthase assembly defects using antibodies against INA17 and other complex components

  • Identifying alterations in INA17 localization or post-translational modifications

• Mechanistic studies:

  • Immunoprecipitation to identify altered protein interactions in disease states

  • Tracking changes in INA17 incorporation into ATP synthase complexes

  • Monitoring compensatory responses to ATP synthase dysfunction

• Therapeutic development:

  • Screening for compounds that restore proper INA17 function or complex assembly

  • Developing antibody-based approaches to modulate ATP synthase assembly

• Model validation:

  • Confirming phenotypes in cellular and animal models of mitochondrial disorders

  • Validating genetic manipulations targeting INA17 or interacting partners

The effectiveness of INA17 antibodies in disease research depends on their ability to detect subtle changes in protein localization and complex formation that may not be apparent from expression level analysis alone.

What considerations are important when using INA17 antibodies in developing research technologies?

When integrating INA17 antibodies into new research technologies, researchers should consider:

• Immobilization strategies:

  • Oriented attachment to preserve antigen-binding sites

  • Surface chemistry compatible with antibody stability

  • Spacer length to reduce steric hindrance

• Detection system compatibility:

  • Labeling with fluorophores, enzymes, or nanoparticles

  • Signal-to-noise optimization for sensitive detection

  • Multiplexing with other mitochondrial markers

• Microenvironment effects:

  • Buffer conditions that maintain antibody stability and specificity

  • Temperature sensitivity of binding interactions

  • Potential interference from sample components

• Validation standards:

  • Establishing quantitative performance metrics

  • Developing appropriate calibration materials

  • Creating positive and negative control samples

Researchers should follow the biophysics-informed modeling approach combined with extensive validation, which has broad applicability beyond antibodies and offers a powerful toolset for designing proteins with desired physical properties .